1843 related articles for article (PubMed ID: 34888843)
21. New Insights into Immune Cells and Immunotherapy for Thyroid Cancer.
Tao Y; Li P; Feng C; Cao Y
Immunol Invest; 2023 Nov; 52(8):1039-1064. PubMed ID: 37846977
[TBL] [Abstract][Full Text] [Related]
22. HVEM network signaling in cancer.
Šedý JR; Ramezani-Rad P
Adv Cancer Res; 2019; 142():145-186. PubMed ID: 30885361
[TBL] [Abstract][Full Text] [Related]
23. BTLA-HVEM Checkpoint Axis Regulates Hepatic Homeostasis and Inflammation in a ConA-Induced Hepatitis Model in Zebrafish.
Shi W; Shao T; Li JY; Fan DD; Lin AF; Xiang LX; Shao JZ
J Immunol; 2019 Nov; 203(9):2425-2442. PubMed ID: 31562209
[TBL] [Abstract][Full Text] [Related]
24. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
Šedý JR; Bjordahl RL; Bekiaris V; Macauley MG; Ware BC; Norris PS; Lurain NS; Benedict CA; Ware CF
J Immunol; 2013 Jul; 191(2):828-36. PubMed ID: 23761635
[TBL] [Abstract][Full Text] [Related]
25. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
[TBL] [Abstract][Full Text] [Related]
26. IL2RA
Pan Z; Bao L; Lu X; Hu X; Li L; Chen J; Jin T; Zhang Y; Tan Z; Huang P; Ge M
Biochim Biophys Acta Mol Basis Dis; 2023 Jan; 1869(1):166591. PubMed ID: 36328145
[TBL] [Abstract][Full Text] [Related]
27. Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients.
Bai Y; Shi Y; Li Y; Cai B; Zou Y; Wang L
Transpl Immunol; 2013 Jan; 28(1):38-47. PubMed ID: 23165214
[TBL] [Abstract][Full Text] [Related]
28. Distinct Changes of BTLA and HVEM Expressions in Circulating CD4
Liu J; Li J; He M; Zhang GL; Zhao Q
J Immunol Res; 2018; 2018():4561571. PubMed ID: 30116751
[TBL] [Abstract][Full Text] [Related]
29. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.
Nakazawa T; Nagasaka T; Yoshida K; Hasegawa A; Guo F; Wu D; Hiroshima K; Katoh R
BMC Endocr Disord; 2022 Aug; 22(1):204. PubMed ID: 35971106
[TBL] [Abstract][Full Text] [Related]
30. Unconventional ligand activation of herpesvirus entry mediator signals cell survival.
Cheung TC; Steinberg MW; Oborne LM; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6244-9. PubMed ID: 19332782
[TBL] [Abstract][Full Text] [Related]
31. [Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model].
Han LF; Qiu WM; Hu C; Wang L; Yao HX; Xiong SY; Meng M; Fang Y; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):603-8. PubMed ID: 21029617
[TBL] [Abstract][Full Text] [Related]
32. Targeting BTLA with the peptide inhibitor HVEM(14-39) - A new way to restore the activity of T cells in melanoma.
Wojciechowicz K; Kuncewicz K; Rutkowski J; Jassem J; Rodziewicz-Motowidło S; Wardowska A; Spodzieja M
Biomed Pharmacother; 2024 Jun; 175():116675. PubMed ID: 38733770
[TBL] [Abstract][Full Text] [Related]
33. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.
Murphy TL; Murphy KM
Annu Rev Immunol; 2010; 28():389-411. PubMed ID: 20307212
[TBL] [Abstract][Full Text] [Related]
34. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.
Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
[TBL] [Abstract][Full Text] [Related]
35. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.
Min IM; Shevlin E; Vedvyas Y; Zaman M; Wyrwas B; Scognamiglio T; Moore MD; Wang W; Park S; Park S; Panjwani S; Gray KD; Tassler AB; Zarnegar R; Fahey TJ; Jin MM
Clin Cancer Res; 2017 Dec; 23(24):7569-7583. PubMed ID: 29025766
[No Abstract] [Full Text] [Related]
36. The intrahepatic expression and distribution of BTLA and its ligand HVEM in patients with HBV-related acute-on-chronic liver failure.
Xu H; Cao D; Guo G; Ruan Z; Wu Y; Chen Y
Diagn Pathol; 2012 Oct; 7():142. PubMed ID: 23067542
[TBL] [Abstract][Full Text] [Related]
37. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
Cai G; Anumanthan A; Brown JA; Greenfield EA; Zhu B; Freeman GJ
Nat Immunol; 2008 Feb; 9(2):176-85. PubMed ID: 18193050
[TBL] [Abstract][Full Text] [Related]
38. Structural Basis of CD160:HVEM Recognition.
Liu W; Garrett SC; Fedorov EV; Ramagopal UA; Garforth SJ; Bonanno JB; Almo SC
Structure; 2019 Aug; 27(8):1286-1295.e4. PubMed ID: 31230945
[TBL] [Abstract][Full Text] [Related]
39. Inhibitor of apoptosis protein Livin promotes tumor progression and chemoradioresistance in human anaplastic thyroid cancer.
Kim HK; Kim SA; Jung EK; Lee KH; Lee JK; Kang HC; Joo YE; Lim SC; Yoon TM
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649820
[TBL] [Abstract][Full Text] [Related]
40. HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160.
Liu W; Chou TF; Garrett-Thomson SC; Seo GY; Fedorov E; Ramagopal UA; Bonanno JB; Wang Q; Kim K; Garforth SJ; Kakugawa K; Cheroutre H; Kronenberg M; Almo SC
J Exp Med; 2021 Dec; 218(12):. PubMed ID: 34709351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
